SynthesisMolecular psychiatry2018
Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD.
Synthesis in Molecular psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03730870 (Assessment of Pharmacogenomics Testing for Improving Pediatric ADHD Psychopharmacological Treatment), which is not on this map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Pharmacogenomics Testing for Improving Pediatric ADHD Psychopharmacological Treatment: A Randomized Controlled Trial
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- A multi-cohort assessment of the polygenic prediction in ADHD treatment response.Psychiatry research · 2026Pooled it
- Effect of adipose-related parameters on mortality in patients with liver cirrhosis: a meta-analysis.Annals of medicine · 2025Pooled it
- Pooled it
- Presence of recombination hotspots throughout SLC6A3.PloS one · 2019Trial
- Review
- Common and rare variant contributions to discontinuation of stimulant treatment in ADHD.Translational psychiatry · 2026Article
- Can response to ADHD medication be predicted?European child & adolescent psychiatry · 2025Observational
- Single-dose methylphenidate induces shift in functional connectivity associated with positive longer term clinical response in adult attention-deficit/hyperactivity disorder.Scientific reports · 2025Article
- Genome data based deep learning identified new genes predicting pharmacological treatment response of attention deficit hyperactivity disorder.Translational psychiatry · 2025Article
- Dopamine Transporter andJournal of child and adolescent psychopharmacology · 2024Article
- Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.European journal of clinical pharmacology · 2024Article
- An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder.Discover mental health · 2023Review
- Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications.Frontiers in pharmacology · 2023Review
- Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review.Neurology and therapy · 2022Review
- Treatment biomarkers for ADHD: Taking stock and moving forward.Translational psychiatry · 2022Review
- Influence of Receptor Polymorphisms on the Response to α-Adrenergic Receptor Blockers in Pheochromocytoma Patients.Biomedicines · 2022Article
- Influence ofInternational journal of environmental research and public health · 2022Article
- Review and Meta-analysis on the Impact of theBiological psychiatry global open science · 2022Article
- The dopamine transporter gene SLC6A3: multidisease risks.Molecular psychiatry · 2022Article
- Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.Frontiers in human neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Stimulant medication has long been effective in treating attention-deficit/hyperactivity disorder (ADHD) and is currently the first-line pharmacological treatment for children. Both methylphenidate and amphetamine modulate extracellular catecholamine levels through interaction with dopaminergic, adrenergic and serotonergic system components; it is therefore likely that catecholaminergic molecular components influence the effects of ADHD treatment. Using meta-analysis, we sought to identify predictors of pharmacotherapy to further the clinical implementation of personalized medicine. We identified 36 studies (3647 children) linking the effectiveness of methylphenidate treatment with DNA variants. Pooled-data revealed a statistically significant association between single nucleotide polymorphisms (SNPs) rs1800544 ADRA2A (odds ratio: 1.69; confidence interval: 1.12-2.55), rs4680 COMT (odds ratio (OR): 1.40; confidence interval: 1.04-1.87), rs5569 SLC6A2 (odds ratio: 1.73; confidence interval: 1.26-2.37) and rs28386840 SLC6A2 (odds ratio: 2.93; confidence interval: 1.76-4.90), and, repeat variants variable number tandem repeat (VNTR) 4 DRD4 (odds ratio: 1.66; confidence interval: 1.16-2.37) and VNTR 10 SLC6A3 (odds ratio: 0.74; confidence interval: 0.60-0.90), whereas the following variants were not statistically significant: rs1947274 LPHN3 (odds ratio: 0.95; confidence interval: 0.71-1.26), rs5661665 LPHN3 (odds ratio: 1.07; confidence interval: 0.84-1.37) and VNTR 7 DRD4 (odds ratio: 0.68; confidence interval: 0.47-1.00). Funnel plot asymmetry among SLC6A3 studies was identified and attributed largely to small study effects. Egger's regression test and Duval and Tweedie's 'trim and fill' were used to examine and correct for publication bias. These findings have major implications for advancing our therapeutic approach to childhood ADHD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.